PTN — Palatin Technologies, Inc.

Summary of Palatin's Q3 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $3.9 million in collaboration and license revenue, a significant increase from $0 in the prior year, primarily due to the Altanispac agreement.
• Operating Expenses: Totaled $5.5 million, up from $4.8 million year-over-year, driven by higher compensation costs and professional fees.
• Net Cash Used in Operations: $4.4 million, a decrease from $5.4 million in the prior year, attributed to the recognized collaboration revenue.
• Net Loss: $1.4 million or $0.37 per share, improved from a net loss of $4.8 million or $9.13 per share in the prior year.
• Cash Position: As of March 31, 2026, cash and cash equivalents were $10.2 million, with expected receivables of $2.2 million, sufficient to fund operations through June 30, 2027.

2. Strategic Updates and Business Highlights

• Palatin is advancing its melanocortin-4 receptor (MC4R) agonist therapies targeting rare obesity disorders, emphasizing improved tolerability and usability.
• The lead clinical asset, a once-weekly MC4R selective peptide agonist, is on track for an initial new drug application (NDA) submission in Q4 2026.
• The company is also developing next-generation oral small molecule candidates with improved selectivity and potency, aiming for an IND submission in H1 2027.
• Strategic partnerships, including collaborations with Boehringer Ingelheim and Altanispac Labs, are generating non-dilutive capital and potential royalties.

3. Forward Guidance and Outlook

• Palatin expects to submit an IND for the peptide program in Q4 2026 and for the oral small molecule program in H1 2027.
• The company is confident that existing cash resources and receivables will sustain operations through mid-2027, allowing continued development of its pipeline.

4. Bad News, Challenges, or Points of Concern

• The decision to discontinue the PL-7737 compound was based on its inability to meet the desired selectivity and dosing profiles, raising concerns about the competitiveness of the pipeline.
• The company faces competitive pressures from established players like Rhythm Pharmaceuticals, which has already launched products in the MC4R space.
• The timeline for the oral small molecule program has been pushed back by approximately a year compared to PL-7737, which may affect market entry.

5. Notable Q&A Insights

• CEO Carl Spana emphasized the importance of developing best-in-class compounds, noting that the decision to discontinue PL-7737 was multifactorial, including the emergence of better candidates.
• The company aims to eliminate hyperpigmentation associated with MC1R activity in its new oral compounds, with ongoing preclinical studies to validate this goal.
• Spana indicated that both the peptide and oral small molecule programs are seen as equal priorities, depending on resource availability.
• The IND-enabling studies for the peptide program are progressing well, with no significant issues reported.

Overall, Palatin is making strategic advancements in its obesity pipeline while navigating competitive pressures and focusing on delivering differentiated therapies.